CHM-1

CAS No. 154554-41-3

CHM-1( NSC656158 )

Catalog No. M27612 CAS No. 154554-41-3

CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 31 In Stock
10MG 53 In Stock
25MG 114 In Stock
50MG 155 In Stock
100MG 233 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CHM-1
  • Note
    Research use only, not for human use.
  • Brief Description
    CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo.
  • Description
    CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo.(In Vitro):CHM-1 (0-10 μM; 24 hours) significantly increased the binding of cyclin B1 to Cdc2 and induced change in expressed and phosphorylated status of G2-M regulators in HA22T cells. CHM-1 (0-100μM; 24 hours) induced significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells with an IC50 of 0.75 μM).(In Vivo):In male severe combined immunodeficient mice, CHM-1 (10 mg/kg; i.p.) induced inhibition of HA22T tumor growth in a dose-dependent manner.
  • In Vitro
    CHM-1 (0-100μM; 24 hours) induces significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells (IC50 = 0.75 μM).CHM-1 (0-10 μM; 24 hours) significantly increases the binding of cyclin B1 to Cdc2 in HA22T cells. Cell Viability Assay Cell Line:HA22T, Hep3B, and HepG2 cells Concentration:0-100 μM Incubation Time:24 hours Result:Induced G2-M arrest of the cell cycle followed by apoptosis.Western Blot Analysis Cell Line:HA22T cells Concentration:0-10 μM Incubation Time:24 hours Result:Induced change in expressed and phosphorylated status of G2-M regulators in human hepatocellular carcinoma cells.
  • In Vivo
    CHM-1 (10 mg/kg; I.p.) induces a dose-dependent inhibition of HA22T tumor growth. Animal Model:Male severe combined immunodeficient mice (HA22T)Dosage:10 mg/kg Administration:I.p.Result:Induced a dose-dependent inhibition of HA22T tumor growth.
  • Synonyms
    NSC656158
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Antibiotic|P-glycoprotein
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    154554-41-3
  • Formula Weight
    283.258
  • Molecular Formula
    C16H10FNO3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 5 mg/mL (17.65 mM)
  • SMILES
    Fc1ccccc1-c1cc(=O)c2cc3OCOc3cc2[nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Phung-Ba V et al. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol. 1995 Jan 16;288(2):187-92.
molnova catalog
related products
  • ZZW-115 hydrochlorid...

    ZZW-115 hydrochloride inhibits the activity of NUPR1.

  • AG 1406

    AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.

  • Pamrevlumab

    Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).